5:06 PM
 | 
May 15, 2019
 |  BC Extra  |  Clinical News

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's first round of Quick Takes on selected abstracts.

Iovance gains on 44% ORR for LN-145 in cervical cancer
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) jumped $2.10 (19%) to $13.33 in after-hours trading Wednesday on data from the Phase II innovaTIL-04 trial showing that LN-145 led to an objective response rate (ORR) of 44% among 27 evaluable patients with recurrent, metastatic or persistent cervical carcinoma. The autologous tumor infiltrating lymphocyte (TIL)-based T cell therapy led to one complete response, nine partial responses and two unconfirmed...

Read the full 509 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >